- Kythera Biopharmaceuticals (KYTH -0.3%) submits a Marketing Authorization Application (MAA) in Europe seeking approval for the use of ATX-101 (deoxycholic acid) injection for reducing submental fat (double chin) in patients who are experiencing a negative psychological impact from their appearance. The MAA was submitted under the Decentralized Procedure with Sweden as the Reference Member State.
- The FDA approved the product, branded as Kybella, in April. Allergan bought the company for $2.1B in June.